Search Results for 'asco'

asco published presentations and documents on DocSlides.

by phoebe-click

. Highlights from the Annual Clinical Meeting. G...

DISCOVER THE AWESOME POWER OF THE ASCO LOW VOLTAGE 7000 SERIES GENERA

DISCOVER THE AWESOME POWER OF THE ASCO LOW VOLTAGE 7000 SERIES GENERA

by conchita-marotz

The ASCO 7000 ERIES Generator Paralleling Control...

GIULIANA D’AURIA UOC Oncologia ASL Roma 2

GIULIANA D’AURIA UOC Oncologia ASL Roma 2

by hadley

Osp. . Pertini-S.Eugenio-CTO. Therapeutic. . app...

Meeting summary ASCO GU 2020,

Meeting summary ASCO GU 2020,

by patricia

San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...

CONKO-007: Chemoradiotherapy vs

CONKO-007: Chemoradiotherapy vs

by davies

Chemotherapy Alone for Unresectable . Locally Adva...

Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final

Alemtuzumab added to CHOP for treatment of peripheral T-cell lymphoma (pTNHL) of the elderly: Final

by thegagn

Presented By Lorenz Trumper at 2016 ASCO Annual Me...

HER2 TESTING IN BREAST CANCER

HER2 TESTING IN BREAST CANCER

by danika-pritchard

Clinical Practice Guideline Update. American Soci...

Genetic plasma cell signatures in high-risk smoldering myel

Genetic plasma cell signatures in high-risk smoldering myel

by trish-goza

Presented By Sham Mailankody at 2016 ASCO Annual ...

Advances in the Immunotherapy of Solid Tumors

Advances in the Immunotherapy of Solid Tumors

by myesha-ticknor

Malignant Melanoma. (8 minutes). Antoni Ribas, M....

HER2 TESTING IN BREAST CANCER

HER2 TESTING IN BREAST CANCER

by danika-pritchard

Clinical Practice Guideline Update. American Soci...

Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function

Randomized Comparison of Adjuvant Aromatase Inhibitor <br />Exemestane plus Ovarian Function

by tatiana-dople

Presented By Olivia Pagani at 2014 ASCO Annual Me...

Denise A. Yardley, MD Sarah Cannon Research Institute

Denise A. Yardley, MD Sarah Cannon Research Institute

by lily

Senior Investigator, . Breast Cancer Research. Ten...

mCODE Community of Practice Monthly Meeting

mCODE Community of Practice Monthly Meeting

by jocelyn

Chairs – Rob Dingwell & Zeshan Rajput. Suppo...

Jchem applications in Medchem

Jchem applications in Medchem

by StarsAndStripes

Prediction. . and. . Data Sorting. Zhengtao. Li...

Presented at the American Society of Clinical Oncology ASCO Annual Mee

Presented at the American Society of Clinical Oncology ASCO Annual Mee

by eliza

8 2021Patientswithhigh-doselymphodepletionCohort2w...

Immunotherapy – the good news and the bad

Immunotherapy – the good news and the bad

by medshair

Associate Professor Philip Beale. Chair ANZGOG Cli...

Immunotherapy – the good news and the bad

Immunotherapy – the good news and the bad

by warlikebikers

Associate Professor Philip Beale. Chair ANZGOG Cli...

ASCO 2012 Review Gynecologic Cancer

ASCO 2012 Review Gynecologic Cancer

by welnews

Nelson Teng, M.D., Ph.D.. Director, Gynecologic On...

Behandeling van het recidief ovariumcarcinoom

Behandeling van het recidief ovariumcarcinoom

by sandsomber

Ignace Vergote MD PhD FACS FSPS. Chairman, Leuven ...

Best of ASCO GU Session Sandy Srinivas.MD

Best of ASCO GU Session Sandy Srinivas.MD

by experimentgoogle

Stanford University. Outline. Abstract #4. :. . I...

Ovarian cancer with update from ASCO 2013

Ovarian cancer with update from ASCO 2013

by karlyn-bohler

Siew. . wei. . wong. Oncology registrar. Epidem...

Lurbinectedin + atezolizumab as first-line

Lurbinectedin + atezolizumab as first-line

by mitsue-stanley

Lurbinectedin + atezolizumab as first-line mainten...

ASCO 2019 NSCLC - PARP & Chemotherapy

ASCO 2019 NSCLC - PARP & Chemotherapy

by mitsue-stanley

ASCO 2019 NSCLC - PARP & Chemotherapy REF Stu...

Checkpoint inhibitors for

Checkpoint inhibitors for

by paisley

NSCLC. An update. Solange Peters, MD-PhD. Oncology...

Updates in the systemic treatment for lung

Updates in the systemic treatment for lung

by madeline

cancer: Immunotherapy. Oscar Arrieta MD. Thoracic....

TRK fusion-positive cancer highlights from ASCO 2022

TRK fusion-positive cancer highlights from ASCO 2022

by joanne

Prof. David S. Hong. Medical Oncologist. MD Anders...

Year in Review Prostate Cancer

Year in Review Prostate Cancer

by faith

Emmanuel . S . Antonarakis. , MD. Professor of Onc...

Oncological Surgyery : 1. ASCO:

Oncological Surgyery : 1. ASCO:

by queenie

Lyman. GH, . Bohlke. K, . Khorana. AA, et al. ....

NASPCC: Chemotherapy Options for Advanced Prostate Cancer

NASPCC: Chemotherapy Options for Advanced Prostate Cancer

by ceila

Jeanny B. Aragon-Ching, M.D., F.A.C.P.. Clinical P...

nmCRPC ASCO GU 2018 Bobby Shayegan, MD FRCSC

nmCRPC ASCO GU 2018 Bobby Shayegan, MD FRCSC

by kylie

Associate Professor & Head. David . Braley. &...

Broadening Eligibility Criteria to Make Clinical Trials More Representative

Broadening Eligibility Criteria to Make Clinical Trials More Representative

by elena

Joint Recommendations of the American Society of C...

ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgki

ECHELON-1: OS Analysis of First-line Brentuximab Vedotin + AVD vs ABVD in Advanced Classical Hodgki

by winnie

Supported by educational grants from AbbVie, Astra...

Targeting EGFR Exon 20 insertions

Targeting EGFR Exon 20 insertions

by unita

Gregory J. Riely. November 2021. What about those ...

Meeting summary asco 2020, virtual meeting

Meeting summary asco 2020, virtual meeting

by neo548

Brittni. . Prosdocimo. , . MSN, RN, . BMTCN. . U...

ASCO Update 2012:

ASCO Update 2012:

by tatyana-admore

Gastrointestinal Malignancies. Thomas J. Semrad M...

Membership Application Every Oncology Professional Everywhere Should be an ASCO Member

Membership Application Every Oncology Professional Everywhere Should be an ASCO Member

by min-jolicoeur

EXPERIENCE THE VALUE OF ASCOS GLOBAL COMMUNITY Th...

Understanding Bubbly Episodes By ASCO M

Understanding Bubbly Episodes By ASCO M

by alexa-scheidler

C ARVALHO A LBERTO ARTIN AND AUME ENTURA Wealth ...

asco This playset is an accessory for the Fiasco role

asco This playset is an accessory for the Fiasco role

by giovanna-bartolotta

This playset is copyright 2013 by James DAmato Fi...

ASCO 388, 390, and 401 Series are 2-Way, normally closed and normally

ASCO 388, 390, and 401 Series are 2-Way, normally closed and normally

by alexa-scheidler

32

Assessment for hereditary colorectal cancer

Assessment for hereditary colorectal cancer

by yoshiko-marsland

Kalyani Maganti, M.D. ASCO. Chromosomes, DNA, and...